摘要
目的 评价乌司他丁治疗多发伤合并重症颅脑损伤的效果.方法 通过检索2003年1月1日～2013年1月1日PubMed、Science Direct、EBSCO Host、EMbase、The Cochrane Library、中国学术期刊全文数据库、万方数据库、维普中文科技期刊全文数据库,对纳入研究的方法学进行评价.研究者对纳入文献的质量进行严格评价和资料提取,使用Review Manager 5.0软件对符合质量标准的随机分组对照临床试验（RCT）行系统评价.结果 7个RCTs共纳入306例患者,其中治疗组（使用乌司他丁）159例,对照组（使用常规治疗）147例,系统评价结果显示：治疗72 h后,相比于对照组,治疗组患者的颅内压并未产生显著变化（P＞0.05）,但肿瘤坏死因子-α含量显著下降,白介素-6含量显著下降,C反应蛋白含量显著下降（P＜0.05）.结论 乌司他丁能显著抑制炎症介质的释放,减轻机体对创伤侵袭的反应,在治疗多发伤合并重症颅脑损伤中表现出显著优越性,值得临床推广.
Objective To evaluate the efficacy of Ulinastatin in the treatment of severe craniocerebral trauma combined with multiple injuries.Methods The methodology of including research was evaluated by searching PubMed,Science Direct,EBSCO Host,EMBASE,The Cochrane Library,CNKI,CECDB CQVIP from January 1st 2003 to January 1st 2013.The researchers strictly evaluated the quality of the included studies and extracted data.The Review Manager 5.0 software was used for system evaluation of RCTs met the quality standards.Results 7 RCTs included 306 patients were selected,there were 159 cases in the treatment group （giving Ulinastatin treatment）,147 cases in the control group （giving conventional treatment）.The results of the system evaluation showed that,after 72 h treatment,compared with the control group,patients of the treatment group had less intracranial pressure changes （P 〉 0.05）,but lower TNF-α level,lower IL-6 level,lower CRP level （P 〈 0.05）.Conclusion Ulinastatin significantly inhibits the release of inflammatory mediators,reduce the body＇s reaction to trauma invasion.Ulinastatin demonstrated significant superiority in the treatment of multiple trauma combined with severe traumatic brain injury,which is worthy to be popularized.
出处
《中国医药导报》
CAS
2014年第6期35-40,共6页
China Medical Herald
关键词
乌司他丁
多发伤
重症颅脑损伤
Ulinastatin
Multiple trauma
Severe craniocerebral injury
